Researchers reviewed existing studies to compare newer blood thinners called DOACs with older ones called VKAs. They focused on people with atrial fibrillation who have a history or risk of falling. The goal was to see which medications might work better at preventing strokes while causing fewer major bleeding events in this specific group.
The analysis combined data from 10 previous studies, including both clinical trials and observational research. It did not report the total number of patients involved. The researchers used statistical methods to rank the different DOACs. They found that among the drugs studied, apixaban ranked highest for reducing the risk of stroke or blood clots. Edoxaban ranked highest for lowering the risk of major bleeding.
No specific safety concerns or side effects were detailed in this review. The main reason to be careful is that the researchers noted the studies they analyzed had moderate to serious risk of bias. This means there could be flaws in how the original research was conducted that might affect the results. Readers should understand this is a statistical analysis of existing data, not a new clinical trial. It suggests some newer blood thinners might have advantages for certain patients, but doctors need to consider individual circumstances and more robust evidence.